Abstract
Fungal diseases are a significant cause of morbidity and mortality worldwide, primarily affecting immunocompromised patients. Aspergillus, Pneumocystis, and Cryptococcus are opportunistic fungi and may cause severe lung disease. They can develop mechanisms to evade the host immune system and colonize or cause lung disease. Current fungal infection treatments constitute a few classes of antifungal drugs with significant fungi resistance development. Amphotericin B (AmB) has a broad-spectrum antifungal effect with a low incidence of resistance. However, AmB is a highly lipophilic antifungal with low solubility and permeability and is unstable in light, heat, and oxygen. Due to the difficulty of achieving adequate concentrations of AmB in the lung by intravenous administration and seeking to minimize adverse effects, nebulized AmB has been used. The pulmonary pathway has advantages such as its rapid onset of action, low metabolic activity at the site of action, ability to avoid first-pass hepatic metabolism, lower risk of adverse effects, and thin thickness of the alveolar epithelium. This paper presented different strategies for pulmonary AmB delivery, detailing the potential of nanoformulation and hoping to foster research in the field. Our finds indicate that despite an optimistic scenario for the pulmonary formulation of AmB based on the encouraging results discussed here, there is still no product registration on the FDA nor any clinical trial undergoing ClinicalTrial.gov.
Funder
Universidade Federal Fluminense (PROPPI/UFF), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) Grant
Programa de Pós Graduação em Neurosciências da Federal Fluminense
Programa de Pós Graduação em Biologia Molecular Celular
Universidade Federal do Estado do Rio de Janeiro
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ) Grants
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Instituto Oswaldo Cruz
Reference241 articles.
1. Pathogenesis of respiratory viral and fungal coinfections;Salazar;Clin. Microbiol. Rev.,2022
2. Aerosolized amphotericin for the treatment of allergic bronchopulmonary aspergillosis;Hayes;Pediatr. Pulmonol.,2010
3. The clinical spectrum of pulmonary aspergillosis;Soubani;Chest,2002
4. Epidemiology and treatment approaches in management of invasive fungal infections;Kriengkauykiat;Clin. Epidemiol.,2011
5. Fungal lung disease;Koltsida;Paediatr. Respir. Rev.,2021
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献